Welcome to The Retina Partners where 15 years of research experience and compassionate care come together to provide exceptional treatment for your vision.
With over 15 years of expertise in clinical research, our team is committed to delivering advanced, cutting-edge treatments in a compassionate, patient-centered environment. We are proud to be at the forefront of retinal research, participating in a variety of clinical trials designed to enhance the care and outcomes for patients with retinal diseases. Our dedication extends beyond clinical excellence—we focus on delivering a personalized and supportive experience, ensuring every patient receives the attention and care they deserve.
Explore the clinical trials we are involved in and discover how our innovative approach can improve your vision and overall well-being
If you are interested in participating in a clinical trial, please speak with one of our physicians at your next appointment or contact us at (877) 3-RETINA.
Ascent (RGX-314-3101)
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Treatment: Gene therapy via surgical procedure vs. standard injections
Duration: up to 108 weeks
Atmosphere (RGX-314-2104)
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD
Treatment: Gene therapy via surgical procedure vs. standard injections
Duration: up to 104 weeks
Burgundy (BP41670)
A Three-part, Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery from the Port Delivery in Patients with Neovascular Age-related Macular Degeneration (Burgundy)
Treatment: Surgical Implant
Duration: 144 weeks
Kyowa 002 (4951-002)
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Neovascular Age-Related Macular Degeneration
Treatment: standard injections for 8 weeks then eye drops
Duration: 56 weeks
Lucia (EYP-1901-302)
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Treatment: implant administered through injection vs standard injections
Duration: 96 weeks
SOL-R (OTX-TKI-2023-AMD-303)
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Treatment: hydrogel implant administered through injection vs standard injections
Duration: 72 weeks
DIAMOND 1 (DX219)
A Phase 2/3 Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema
Treatment: Eye drops
Duration: 52 weeks
Kyowa 003 (4951-003)
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Diabetic Macular Edema
Treatment: standard injections for 8 weeks then eye drops
Duration: 56 weeks
ALXN2040-GA-201
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
DIAMOND 1 (DX219)
A Phase 2/3 Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with DiabeticMacular Edema
HONU (GE43220)
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-related Macular Degeneration
Pagoda (GR40550)
A Phase III, Multicenter, Randomized, Visual Assessor-masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema (Pagoda)
Pavilion (GR41675)
A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)
Portal (GR40549)
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
ShORe (OPT-302-1004)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
SOL (OTX-TKI-2023-AMD-301)
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
